In a boost for Amgen, the U.S. Supreme Court agreed to hear a case in which the company argued a federal appeals court incorrectly determined its patent claims on a cholesterol medication are invalid.
At issue is a long-running battle between Amgen and a pair of rivals — Sanofi and Regeneron Pharmaceuticals — over the market for injectable cholesterol treatments. Amgen filed a lawsuit against the other companies in 2014 for allegedly infringing patents when they sought regulatory approval for their own medication. Both drugs won U.S. regulatory approval the subsequent year.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
